[Chemotherapy for prostate cancer].

Wiener klinische Wochenschrift
Michael RauchenwaldMichael Krainer

Abstract

For many years the benefit of chemotherapy in patients with prostate cancer was thought to be limited to palliation of late-stage disease, and thus this treatment option only became involved in patient care towards the end of the disease process, if at all. However, two landmark phase-III trials with docetaxel-based therapy (TAX 327 and Southwest Oncology Group, SWOG, 9916) have shown a survival benefit for patients with hormone refractory prostate cancer (HRPC) thus prompting a change in patterns of care. With raising interest for chemotherapeutic options and clinical trials for new drugs and new indications (neoadjuvant therapy, adjuvant therapy, increasing PSA levels after local treatment, and hormone sensitive cancer) under way our goal was to review within the context of a multidisciplinary team the available evidence and explore the standard for the medical treatment of prostate cancer outside of clinical trials. We are carefully evaluating the current treatment recommendations based on the available evidence and highlight potential future treatment options but also discuss important clinical topics (treatment until progression versus the advantage of chemo holidays, definition of particular patient subgroups and potentia...Continue Reading

References

Jan 1, 1990·World Health Organization Technical Report Series
Aug 1, 1993·Journal of Pain and Symptom Management·K M Foley, R K Portenoy
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I F TannockK C Murphy
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G HudesB Roth
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P W KantoffN J Vogelzang
Dec 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E J SmallF H Valone
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D M SavareseN J Vogelzang
Nov 17, 2001·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·C VutucG Haidinger
Dec 6, 2001·Proceedings of the National Academy of Sciences of the United States of America·M MercaderE D Kwon
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lazzaro RepettoVittorina Zagonel
Oct 3, 2002·Journal of the National Cancer Institute·Fred SaadUNKNOWN Zoledronic Acid Prostate Cancer Study Group
Jan 10, 2004·The Journal of Urology·Satoko KojimaHaruo Ito
Sep 30, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C BokemeyerP Soubeyran
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Nov 3, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R P AbrattS Oudard
Nov 24, 2004·Cancer·Sam S ChangUNKNOWN Society of Urologic Oncology, Shaumberg, Illinois
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan GoodinRobert S DiPaola
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arif HussainChuanfa Guo
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Phillip G FebboWilliam K Oh
Jul 26, 2005·Journal of the National Comprehensive Cancer Network : JNCCN·Jeffrey CrawfordUNKNOWN National Comprehensive Cancer Network
Jul 28, 2005·European Urology·G AusUNKNOWN European Association of Urology
Oct 4, 2005·Clinical Prostate Cancer·Kathleen W BeekmanW Kevin Kelly
Nov 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dominik R BertholdIan F Tannock
Apr 20, 2006·Journal of the National Cancer Institute·Daniel P PetrylakE David Crawford
May 2, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norihiko TsuchiyaTomonori Habuchi
May 9, 2006·Urologic Oncology·Mark GarzottoTomasz M Beer
Jul 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J SmallRobert M Hershberg
Sep 8, 2006·BJU International·Cora N SternbergJohn M Fitzpatrick
Sep 16, 2006·International Journal of Cancer. Journal International Du Cancer·Anna-K Thomas-KaskelHendrik Veelken
Sep 20, 2006·BJU International·John AndersonJohn M Fitzpatrick
Sep 30, 2006·European Urology·Fabio Calabrò, Cora N Sternberg
Oct 21, 2006·The Cochrane Database of Systematic Reviews·Mike ShelleyMalcolm D Mason
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Noah M HahnChristopher J Sweeney
Dec 13, 2006·Critical Reviews in Oncology/hematology·Amy M LinEric J Small
Jan 9, 2007·Urologic Oncology·John PendletonCharles J Rosser

❮ Previous
Next ❯

Citations

Jul 21, 2012·Wiener klinische Wochenschrift·Michael RauchenwaldMichael Krainer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.